Galen Limited, a leading pharmaceutical sales and marketing company, is proud to announce a significant step in its global expansion by signing an exclusive licensing agreement with Taiwan-based Bora Health Inc.

This partnership grants Bora Health Inc exclusive rights to market and distribute Galen’s innovative product, PKU EASY Microtabs Plus, across Taiwan. Specifically designed for individuals with Phenylketonuria (PKU), Microtabs Plus offers a phenylalanine-free protein substitute, enriched with essential vitamins, minerals, and amino acids.

Galen Limited has successfully launched PKU EASY Microtabs Plus in Germany, the Nordics, and the USA. The company is ambitiously planning to extend its availability even further in the near future. This strategic expansion aims to improve access to effective and convenient care for individuals affected by PKU.

Johnny McGaughey, Galen’s Head of Business Development, expressed his enthusiasm about the collaboration: “Galen is delighted to partner with Bora Health. This agreement supports our mission to improve global healthcare by making our products more accessible, and positively impacting patient outcomes through our shared vision.”

Carol Lin, Associate Director of Domestic Pharma and Overseas Business Development at Bora Health, remarked: “Our partnership with Galen Limited represents a significant step in our ongoing mission to enhance the quality of life for people and patients. Guided by our passion for health, we are committed to delivering exceptional products and services, and this collaboration perfectly aligns with our dedication to customer satisfaction.”

More information on the partnership and Galen’s out licensing opportunities can be found at www.galen-pharma.com